Collaboration to Develop Breast, Prostate Cancer Tests
Portland, OR – The Knight Cancer Institute at Oregon Health & Science University (OHSU) and Cepheid, a leading molecular diagnostics company, have announced a collaboration to develop a menu of advanced molecular diagnostics to be performed on the GeneXpert system.
The collaboration will focus on the development of clinical oncology tests for the GeneXpert system and will establish a system for clinically validating the tests through the Knight Diagnostic Laboratories, a division of the Knight Cancer Institute at OHSU. The alliance includes an exclusive license to OHSU intellectual property in prostate cancer and intellectual property co-developed by Lawrence Berkeley National Laboratory and OHSU in breast cancer.
The collaborative research will be led by Joe W. Gray, Ph.D., Associate Director of Translational Research for the Knight Cancer Institute at OHSU, and Michael Bates, M.D., Cepheid's Vice President, Oncology Research & Development. Initial projects will focus on breast and prostate cancers, including development of Xpert® Breast Cancer Signature, a diagnostic test designed to predict the risk of recurrence in newly diagnosed patients, and Xpert Prostate Cancer Recurrence Risk, a test designed to predict the likelihood of recurrence in patients following surgery, as well as other prostate cancer applications. Each assay will take advantage of the GeneXpert system's ability to quantitatively assess multiple RNA targets extracted from formalin-fixed, paraffin-embedded tumor tissue.
"Cepheid is honored to be working with Dr. Gray and his colleagues at OHSU with the goal of making their impressive scientific discoveries in the field of oncology and personalized medicine widely available to physicians for the benefit of their patients," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "We look forward to partnering with OHSU to add a number of high impact oncology tests to the Xpert portfolio, delivering the most advanced diagnostic solutions for cancer patients while also achieving the accuracy, reproducibility, rapid turn-around-time, and cost-effectiveness that characterize the GeneXpert platform." Continue>
Posted in: Smart Moves | June 18, 2013
Posted in: Smart Moves | July 23, 2013
Posted in: Smart Moves | January 7, 2014